Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenggong Li

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
BMC Cancer|January 25, 2022
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysisWenjing Luo, Chenggong Li, Yinqiang Zhang, et al.
Annals of Hematology|October 9, 2023
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapyXindi Wang, Chenggong Li, Wenjing Luo, et al.
British Journal of Haematology|October 9, 2022
Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case reportChenggong Li, Jiachen Liu, Jun Deng, et al.
Critical Reviews in Oncology/Hematology|October 10, 2025
Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysisZhihan Chen, Wenjng Luo, Yun Kang, et al.
Cancer Science|June 17, 2025
Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell LymphomaWenjing Luo, Jia Xu, Chenggong Li, et al.
Frontiers in Immunology|July 8, 2022
Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic LeukemiaYinqiang Zhang, Fen Zhou, Zhuolin Wu, et al.
Chinese Medical Journal|April 9, 2025
Effect of interferon induced transmembrane protein 1 ( IFITM1 ) upregulation to cytokine release syndrome in CAR-T-treated B-cell acute lymphoblastic leukemiaMengyi Du, Yinqiang Zhang, Chenggong Li, et al.
Clinical and Translational Medicine|March 20, 2023
Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapyJianghua Wu, Lu Tang, Mengyi Du, et al.
Cancer Medicine|October 22, 2025
BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical TrialWenjing Luo, Yinqiang Zhang, Chenggong Li, et al.
Cytotherapy|April 19, 2023
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphomaWenjing Luo, Chenggong Li, Jianghua Wu, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
BMC Cancer|January 25, 2022
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysisWenjing Luo, Chenggong Li, Yinqiang Zhang, et al.
Annals of Hematology|October 9, 2023
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapyXindi Wang, Chenggong Li, Wenjing Luo, et al.
British Journal of Haematology|October 9, 2022
Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case reportChenggong Li, Jiachen Liu, Jun Deng, et al.
Critical Reviews in Oncology/Hematology|October 10, 2025
Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysisZhihan Chen, Wenjng Luo, Yun Kang, et al.
Cancer Science|June 17, 2025
Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell LymphomaWenjing Luo, Jia Xu, Chenggong Li, et al.
Frontiers in Immunology|July 8, 2022
Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic LeukemiaYinqiang Zhang, Fen Zhou, Zhuolin Wu, et al.
Chinese Medical Journal|April 9, 2025
Effect of interferon induced transmembrane protein 1 ( IFITM1 ) upregulation to cytokine release syndrome in CAR-T-treated B-cell acute lymphoblastic leukemiaMengyi Du, Yinqiang Zhang, Chenggong Li, et al.
Clinical and Translational Medicine|March 20, 2023
Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapyJianghua Wu, Lu Tang, Mengyi Du, et al.
Cancer Medicine|October 22, 2025
BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical TrialWenjing Luo, Yinqiang Zhang, Chenggong Li, et al.
Cytotherapy|April 19, 2023
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphomaWenjing Luo, Chenggong Li, Jianghua Wu, et al.
Pageof 3